ProCE Banner Activity

TROP-2 Overview in NSCLC: Expression, Significance, and Therapeutic Rationale

Slideset

Download these slides on the evolving treatment landscape of advanced NSCLC with a focus on the rationale for targeting TROP-2 and the potential role of TROP-2-targeting ADCs.

Released: April 25, 2024

Expiration: April 24, 2025

Share

Faculty

Narjust Florez

Narjust Florez, MD

Associate Director of The Cancer Care Equity Program
Thoracic Medical Oncologist
Dana-Farber Cancer Institute
Assistant Professor of Medicine
Harvard Medical School
Associate Editor, JAMA Oncology
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.